<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764137</url>
  </required_header>
  <id_info>
    <org_study_id>300002089</org_study_id>
    <nct_id>NCT03764137</nct_id>
  </id_info>
  <brief_title>Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer</brief_title>
  <acronym>Panitumumab</acronym>
  <official_title>Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for
      imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node
      involvement. If promising, this data will be used to design larger trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image Quality</measure>
    <time_frame>12 months</time_frame>
    <description>Diagnostic image quality of [89Zr]Panitumumab PET imaging in patients with newly diagnosed colon cancer with nodal involvement. Standardized Uptake Values (SUVs) will be measured.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metastatic Colon Cancer</condition>
  <arm_group>
    <arm_group_label>[89Zr]Panitumumab-PET/MRI patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[89Zr]Panitumumab PET-MRI</intervention_name>
    <description>All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.</description>
    <arm_group_label>[89Zr]Panitumumab-PET/MRI patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 19 years of age.

          -  Diagnosis of colon cancer

          -  Scheduled to undergo surgical resection

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Pregnancy

          -  Inability to lie still for the imaging study

          -  Weight over 350 lbs., due to the scanner bore size

          -  Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)

          -  Inability to receive Omnipaque (iohexol) iodinated contrast

          -  Inability to receive glucagon

          -  Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent

          -  Allergy to contrast imaging agents

          -  Finding or suspicion of distant metastases on CT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Lapi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzanne Lapi, PhD</last_name>
    <phone>205-975-8689</phone>
    <email>lapi@uab.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, RT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Advanced Imaging Facility</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Vetrano, RN</last_name>
      <phone>205-934-4080</phone>
      <email>mvetrano@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Suzanne E. Lapi, PhD</investigator_full_name>
    <investigator_title>Director Cyclotron Facility</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

